Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma

Marilia Barreca, Anastasios Stathis, Arribas, Francesco Bertoni, Gaudio, Emanuele, Sartori, Filippo Spriano, Cascione, Bordone-Pittau, Chiara, Rossi, Napoli, Andrea Rinaldi, Stussi

Research output: Contribution to journalMeeting Abstractpeer-review


PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies
Original languageEnglish
Pages (from-to)40-40
Number of pages1
JournalEuropean Journal of Cancer
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma'. Together they form a unique fingerprint.

Cite this